Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial-Reference-Cited by-同舟云学术

Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial

Published:2019-02 Issue:2 Volume:6 Page:e100-e109
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Nastoupil Loretta J,Lunning Matthew A,Vose Julie M,Schreeder Marshall T,Siddiqi Tanya,Flowers Christopher R,Cohen Jonathon B,Burger Jan A,Wierda William G,O'Brien Susan,Sportelli Peter,Miskin Hari P,Purdom Michelle A,Weiss Michael S,Fowler Nathan H

Publisher

Elsevier BV

Subject

Hematology

Reference28 articles.

1. Pathogenesis of human B cell lymphomas;Shaffer;Annu Rev Immunol,2012

2. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma;Wilson;Nat Med,2015

3. Targeting B cell receptor signalling in cancer: preclinical and clinical advances;Burger;Nat Rev Cancer,2018

4. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma;Davis;Nature,2010

5. Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling;Duhren-von Minden;Nature,2012

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bruton tyrosine kinase inhibitor-related atrial fibrillation and its implications in the treatment of B-cell lymphoma;Frontiers in Cardiovascular Medicine;2024-07-26

2. Targeting CK1δ and CK1ε as a New Therapeutic Approach for Clear Cell Renal Cell Carcinoma;Pharmacology;2024-07-17

3. The Non-hodgkin Lymphoma Treatment and Side Effects: A Systematic Review and Meta-analysis;Recent Patents on Anti-Cancer Drug Discovery;2024-02

4. A Review of Anti-CD20 Antibodies in the Management of B-Cell Lymphomas;Lymphatics;2024-01-05

5. Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review;Current Cancer Therapy Reviews;2024-01